95611-10-2

Basic information

• Product Name: 2-(biotinylamido)ethanol
• Synonyms: 2-(biotinylamido)ethanol
• CAS NO: 95611-10-2
• Molecular Formula: C12H21 N3 O3 S
• Molecular Weight: 287.38
• Mol File: 95611-10-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 667.6°Cat760mmHg
• Flash Point: 357.6°C
• Appearance: /
• Density: 1.225g/cm³
• Vapor Pressure: 1.12E-20mmHg at 25°C
• Refractive Index: 1.541
• CAS DataBase Reference: 2-(biotinylamido)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(biotinylamido)ethanol(95611-10-2)
• EPA Substance Registry System: 2-(biotinylamido)ethanol(95611-10-2)

Safety Data

• Hazardous Substances Data: 95611-10-2(Hazardous Substances Data)

Usage

Chemical composition

Consists of a biotin group attached to a molecule of ethanolamine.

Common usage

Used as a reagent in biotinylation reactions for protein purification, detection, and immobilization.

Water solubility

Highly water-soluble.

pH stability

Stable at a wide range of pH values, making it suitable for various biological and biochemical applications.

Specific binding

Ability to bind specifically to streptavidin or avidin proteins, making it a valuable tool in molecular biology and biotechnology research.

Diagnostic assays

Commonly used in various diagnostic assays.

Bioconjugate labeling

Used in bioconjugate labeling techniques due to its biotin moiety.

InChI:InChI=1/C12H21N3O3S/c16-6-5-13-10(17)4-2-1-3-9-11-8(7-19-9)14-12(18)15-11/h8-9,11,16H,1-7H2,(H,13,17)(H2,14,15,18)/t8-,9-,11-/m0/s1

Upstream product

• 35013-72-0 biotin N-Hydroxysuccinimide ester 
• 141-43-5 ethanolamine 
• 58-85-5 biotin 

Relevant articles and documents

Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer

Pancreatic cancer remains one of the most lethal forms of cancer with a 10-year survival of a significant need for new treatments or more effective strategies to deliver existing treatments. The antimetabolite gemcitabine (Gem) is the most widely used form of chemotherapy for pancreatic cancer treatment, but is known to produce significant side effects when administered systemically. We have previously demonstrated the benefit of combined chemo-sonodynamic therapy (SDT), delivered using oxygen carrying microbubbles (O2MB), as a targeted treatment for pancreatic cancer in a murine model of the disease. In this manuscript, we report the preparation of a biotin functionalised Gem ligand for attachment to O2MBs (O2MB-Gem). We demonstrate the effectiveness of chemo-sonodynamic therapy following ultrasound-targeted-microbubble-destruction (UTMD) of the O2MB-Gem and a Rose Bengal loaded O2MB (O2MB-RB) as a targeted treatment for pancreatic cancer. Specifically, UTMD using the O2MB-Gem and O2MB-RB conjugates reduced the viability of MIA PaCa-2, PANC-1, BxPC3 and T110299 pancreatic cancer cells by >60% (p 80%, p 2MB-Gem conjugate was also determined in healthy non-tumour bearing MF1 mice and revealed no evidence of renal or hepatic damage. Therefore, the results presented in this manuscript suggest that chemo-sonodynamic therapy using the O2MB-Gem and O2MB-RB conjugates, is potentially an effective targeted and safe treatment modality for pancreatic cancer.

SONODYNAMIC THERAPY

The invention relates to microbubble complexes for use in methods of sonodynamic therapy which comprise a microbubble attached to or otherwise associated with one or more linking groups, each linking group being bound to at least one sonosensitising agent and at least one chemotherapeutic agent. It further relates to the microbubble complexes themselves and to pharmaceutical compositions which contain them. The invention is particularly suitable for the treatment of deep-sited tumors, in particular pancreatic cancer.

Transporter-targeted lipid prodrugs of cyclic cidofovir: A potential approach for the treatment of cytomegalovirus retinitis

Cidofovir (CDF) and its cyclic analogue (cCDF) have shown potential in vitro and in vivo antiviral activity against cytomegalovirus (CMV) retinitis. However, hydrophilic nature of CDF may affect cell permeation across lipophilic epithelium and thus limit its effectiveness in the treatment of CMV retinitis. In the present study, we have tested a novel hypothesis, which involves chemical derivatization of cCDF into lipophilic transporter-targeted prodrug [via conjugation with different carbon chain length of lipid raft and targeting moiety (biotin) for sodium-dependent multivitamin transporter (SMVT)]. We have synthesized and characterized three derivatives of cCDF including biotin B-C2-cCDF, B-C6-cCDF, and B-C12-cCDF. Physicochemical properties such as solubility, partition coefficient (n-octanol/water and ocular tissue), bioreversion kinetics, and interaction with SMVT transporter have been determined. Among these novel conjugates, B-C12-cCDF has shown higher interaction to SMVT transporter with lowest half maximal inhibitory concentration value, higher cellular accumulation, and high tissue partitioning. Improvement in physicochemical properties, lipophilicity, and interaction with transporter was observed in the trend of increasing the lipid chain length, that is, B-C12-cCDF > B-C6-cCDF > B-C2-cCDF. These results indicate that transporter-targeted lipid analogue of cCDF exhibits improved cellular accumulation along with higher transporter affinity and hence could be a viable strategy for the treatment of CMV retinitis.